Norway · Delayed Price · Currency is NOK Gentian Diagnostics ASA Earnings Call Transcripts
Fiscal Year 2026
-
Q3 revenue hit a record NOK 51.1 million, with strong EBITDA and growth across Europe, the U.S. and fCAL turbo. Eight R&D projects are active, while pipeline launches and partner contracts remain subject to execution and timing.
-
Record Q2 sales and strong organic growth were driven by robust U.S. and European markets, offsetting softness in China. Gross margin rebounded to 55%, and a new R&D strategy aims to accelerate product launches and diversify revenue beyond Cystatin C and fCAL turbo.
-
Q1 sales were flat at NOK 43.9 million, with 4% organic growth and strong U.S. and European performance. NT-proBNP assay development was discontinued, leading to a NOK 30 million impairment, but resources are being reallocated to a robust pipeline. Confidence remains high for double-digit growth in 2024.
Fiscal Year 2025
-
Record sales and profitability were achieved in 2025, led by Cystatin C’s 32% growth and strong US expansion. A new exclusive partnership and high-sensitivity technology project were announced, while NT-proBNP assay development faced a setback.
-
Q3 2025 saw strong revenue and EBITDA growth, led by U.S. expansion and Cystatin C adoption. Gross margin recovered, and R&D advanced NT-proBNP and other projects. Cautious outlook for China, but U.S. momentum expected to continue.
-
Q2 sales rose 14% year-over-year to NOK 43.6 million, led by strong Cystatin C and U.S. growth. Gross margin dropped to 44% due to one-off production issues, but margins are expected to recover. NT-proBNP assay development remains on track for 2026 launch.
-
Record Q1 sales and profitability driven by strong growth across all products and regions, with Cystatin C and other key assays performing exceptionally. Gross margin exceeded 60%, and the NT-proBNP assay is on track for a 2026 commercial launch.
Fiscal Year 2024
-
Record sales and profitability improvements in 2024, with strong growth in the U.S. and Europe, while China showed early signs of recovery. EFCAL turbo led product growth, and the board proposed the first-ever dividend. NT-proBNP launch remains on track for late 2025.
-
Q3 2024 delivered strong EBITDA and improved gross margin, despite soft revenue growth due to lower China sales. fCAL turbo sales surged 76% year-over-year, and NT-proBNP assay advanced in clinical evaluation with a new patent granted.
-
Q2 sales grew 12% year-over-year to NOK 38.3 million, with EBITDA more than tripling and gross margin rising to 57%. Strong product performance and partner-driven growth continue, though China sales face short-term uncertainty due to tendering changes.